AIT Therapeutics (OTCMKTS:AITB) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday.
A number of other brokerages have also recently issued reports on AITB. Zacks Investment Research cut shares of AIT Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 26th. Roth Capital set a $16.00 target price on shares of AIT Therapeutics and gave the stock a “buy” rating in a report on Saturday, December 2nd. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. AIT Therapeutics has an average rating of “Hold” and a consensus price target of $12.50.
AIT Therapeutics (AITB) opened at $5.20 on Friday. AIT Therapeutics has a 12-month low of $3.51 and a 12-month high of $10.00.
AIT Therapeutics (OTCMKTS:AITB) last issued its quarterly earnings results on Friday, November 3rd. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.59). research analysts predict that AIT Therapeutics will post -2.99 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/02/ait-therapeutics-aitb-stock-rating-upgraded-by-valuengine.html.
AIT Therapeutics Company Profile
AIT Therapeutics, Inc, formerly KokiCare, Inc, is a shell company. The Company is engaged in the discovery and planning phase to develop a real-time, software as a service (SaaS)-based enterprise software application to manage the integration, planning, tracking and management of healthcare assets, which include people, supplies, clinical data, relationships and financial resources of healthcare organizations.
Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.